Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 36, 2014, Pages 13217-13222

  Lee, Young ^a   Berglund, Eric D ^a   Yu, Xinxin ^a   Wang, May Yun ^a   Evans, Matthew R ^a   Scherer, Philipp E ^a   Holland, William L ^a   Charron, Maureen J ^b   Roth, Michael G ^a   Unger, Roger H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Insulin resistance; Type two diabetes

Indexed keywords

CERAMIDE; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN; MESSENGER RNA;

ANIMAL; BLOOD; BODY TEMPERATURE; BODY WEIGHT; C57BL MOUSE; CELL LINE; COMPLICATION; DIET; DISEASE MODEL; DRUG EFFECTS; FEEDING BEHAVIOR; GENETICS; GLUCOSE BLOOD LEVEL; HAMSTER; HYPERGLYCEMIA; HYPERINSULINISM; LIPOGENESIS; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PATHOLOGY; RAT;

ANIMALS; BLOOD GLUCOSE; BODY TEMPERATURE; BODY WEIGHT; CELL LINE; CERAMIDES; CRICETINAE; DIABETES MELLITUS, TYPE 2; DIET; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; GLUCAGON; GLUCAGON-SECRETING CELLS; HYPERGLYCEMIA; HYPERINSULINISM; INSULIN; INSULIN-SECRETING CELLS; LIPOGENESIS; MALE; MICE, INBRED C57BL; RATS; RECEPTORS, GLUCAGON; RNA, MESSENGER;

EID: 84906971483     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1409638111     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention (2014) National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 (US Department of Health and Human Services, Atlanta).
2. International Diabetes Foundation (2014) IDF Diabetes Atlas (International Diabetes Foundation, Brussels).
3. Lee Y, et al. (1994) Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA 91(23):10878-10882.
4. Zhou YT, et al. (1998) Enhanced de novo lipogenesis in the leptin-unresponsive pancreatic islets of prediabetic Zucker diabetic fatty rats: Role in the pathogenesis of lipotoxic diabetes. Diabetes 47(12):1904-1908.
5. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37(12):1595-1607.
6. Ford ES (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28(11):2745-2749.
7. Petersen KF, Shulman GI (2006) New insights into the pathogenesis of insulin resistance in humans using magnetic resonance spectroscopy. Obesity (Silver Spring) 14 (Suppl 1):34S-40S.
8. Leichman JG, Lavis VR, Aguilar D, Wilson CR, Taegtmeyer H (2006) The metabolic syndrome and the heart-A considered opinion. Clin Res Cardiol 95(Suppl 1):i134-i141.
9. Morelli M, et al. (2013) Ectopic fat: The true culprit linking obesity and cardiovascular disease? Thromb Haemost 110(4):651-660.
10. Borradaile NM, et al. (2006) Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J Lipid Res 47(12):2726-2737.
11. Weinberg JM (2006) Lipotoxicity. Kidney Int 70(9):1560-1566.
12. Weir GC, et al. (2009) Towards better understanding of the contributions of overwork and glucotoxicity to the beta-cell inadequacy of type 2 diabetes. Diabetes Obes Metab 11(Suppl 4):82-90.
13. Tuomi T, et al. (2014) The many faces of diabetes: A disease with increasing heterogeneity. Lancet 383(9922):1084-1094.
14. Watson JD (2014) Type 2 diabetes as a redox disease. Lancet 383(9919):841-843.
15. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60(2):391-397.
16. Lee Y, et al. (2012) Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci USA 109(37):14972-14976.
17. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH (1984) Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 74(6):2296-2299.
18. Kawamori D, et al. (2009) Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 9(4):350-361.
19. Raskin P, Unger RH (1978) Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med 299(9):433-436.
20. Aydin I, Raskin P, Unger RH (1977) The effect of short-term intravenous insulin administration on the glucagon response to a carbohydrate meal in adult onset and juvenile type diabetes. Diabetologia 13(6):629-636.
21. Conarello SL, et al. (2007) Glucagon receptor knockout mice are resistant to dietinduced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50(1):142- 150.
22. Yi P, Park JS, Melton DA (2013) Betatrophin: A hormone that controls pancreatic β cell proliferation. Cell 153(4):747-758.
23. Kersten S (2001) Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2(4):282-286.
24. Biddinger SB, et al. (2008) Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 7(2):125-134.
25. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: A pathogenic paradox. Cell Metab 7(2):95-96.
26. Shimomura I, et al. (1999) Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 96(24):13656-13661.
27. Mehran AE, et al. (2012) Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab 16(6):723-737.
28. Cherrington AD (1999) Banting lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48(5):1198-1214.
29. Berglund ED, et al. (2012) Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest 122(3):1000-1009.
30. Unger RH, Orci L (2001) Diseases of liporegulation: New perspective on obesity and related disorders. FASEB J 15(2):312-321.
31. Summers SA, Garza LA, Zhou H, Birnbaum MJ (1998) Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 18(9):5457-5464.
32. Holland WL, et al. (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5(3):167-179.
33. Shimabukuro M, Zhou YT, Lee Y, Unger RH (1998) Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273(6):3547-3550.
34. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922) Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12(3):141-146.
35. Cahill GF, Jr (1971) The banting memorial lecture 1971. Physiology of insulin in man. Diabetes 20(12):785-799.
36. Samols E, Marri G, Marks V (1965) Promotion of insulin secretion by glucagon. Lancet 2(7409):415-416.
37. Unger RH (2008) Reinventing type 2 diabetes: Pathogenesis, treatment, and prevention. JAMA 299(10):1185-1187.
38. Margolis KL, et al. (2014) Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: The ACCORD randomized trial. Diabetes Care 37(6):1721-1728.
39. Berglund ED, et al. (2009) Hepatic energy state is regulated by glucagon receptor signaling in mice. J Clin Invest 119(8):2412-2422.
40. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226(1):497-509.